Canagliflozin ameliorates hypobaric hypoxia-induced pulmonary arterial hypertension by inhibiting pulmonary arterial smooth muscle cell proliferation

ABSTRACTPulmonary arterial hypertension (PAH) is a disease with a high mortality and few treatment options to prevent the development of pulmonary vessel remodeling, pulmonary vascular resistance, and right ventricular failure. Canagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, is or...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Luxun Tang, Qi Cai, Xiao Wang, Xiaoyu Li, Xiuchuan Li, Lianglong Chen, Yongjian Yang
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Taylor & Francis Group 2023-12-01
Edice:	Clinical and Experimental Hypertension
Témata:	Canagliflozin pulmonary arterial hypertension sodium-glucose cotransporter 2 inhibitor pulmonary arterial smooth muscle cell proliferation AMP-activated protein kinase
On-line přístup:	https://www.tandfonline.com/doi/10.1080/10641963.2023.2278205
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!